220 related articles for article (PubMed ID: 22194993)
1. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.
Zuco V; De Cesare M; Cincinelli R; Nannei R; Pisano C; Zaffaroni N; Zunino F
PLoS One; 2011; 6(12):e29085. PubMed ID: 22194993
[TBL] [Abstract][Full Text] [Related]
2. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
3. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.
Rathinasamy K; Jindal B; Asthana J; Singh P; Balaji PV; Panda D
BMC Cancer; 2010 May; 10():213. PubMed ID: 20482847
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Dowdy SC; Jiang S; Zhou XC; Hou X; Jin F; Podratz KC; Jiang SW
Mol Cancer Ther; 2006 Nov; 5(11):2767-76. PubMed ID: 17121923
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
8. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Huang P; Almeciga-Pinto I; Jarpe M; van Duzer JH; Mazitschek R; Yang M; Jones SS; Quayle SN
Oncotarget; 2017 Jan; 8(2):2694-2707. PubMed ID: 27926524
[TBL] [Abstract][Full Text] [Related]
9. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.
Bajbouj K; Mawrin C; Hartig R; Schulze-Luehrmann J; Wilisch-Neumann A; Roessner A; Schneider-Stock R
J Neurooncol; 2012 May; 107(3):503-16. PubMed ID: 22270849
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
[TBL] [Abstract][Full Text] [Related]
11. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
[TBL] [Abstract][Full Text] [Related]
12. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
14. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
Marlow LA; Bok I; Smallridge RC; Copland JA
Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
[TBL] [Abstract][Full Text] [Related]
15. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
[TBL] [Abstract][Full Text] [Related]
16. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
[TBL] [Abstract][Full Text] [Related]
17. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
18. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
Rai A; Surolia A; Panda D
PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
[TBL] [Abstract][Full Text] [Related]
19. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Yang YT; Balch C; Kulp SK; Mand MR; Nephew KP; Chen CS
Neoplasia; 2009 Jun; 11(6):552-63, 3 p following 563. PubMed ID: 19484144
[TBL] [Abstract][Full Text] [Related]
20. [Effect of trichostatin A and paclitaxel on the growth and apoptosis of lung adenocarcinoma cell lines].
Zhang S; Wang XA; Zhang QC; Jiang SJ
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):492-6. PubMed ID: 22967465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
